Cogniant is an AI-assisted digital health platform that passively collects digital biomarkers from diverse patient populations to enhance the efficacy of clinical trials for neurological and psychiatric disorders. By providing real-time data for expansive phenotyping and clinical state prediction, Cogniant bridges the gap between clinical trial outcomes and real-world effectiveness.
Funding
$191K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
RSSTWFounders
Product
Problem
Clinical trials for neurological and psychiatric disorders often struggle to capture real-world patient data, leading to a disconnect between trial outcomes and the actual effectiveness of treatments. Traditional methods rely heavily on infrequent, subjective assessments, failing to provide a comprehensive understanding of a patient's condition outside of a controlled clinical setting. This lack of continuous, objective data hinders the development of personalized treatments and the accurate measurement of therapeutic impact.
Solution
Cogniant offers an AI-assisted digital health platform that passively collects digital biomarkers from patients' mobile devices to enhance clinical trials for neurological and psychiatric disorders. The platform captures relevant data for expansive phenotyping, clinical state prediction, and outcomes measurement, providing researchers and clinicians with a more complete picture of patient health. By continuously monitoring patients in their daily lives, Cogniant bridges the gap between clinical trial results and real-world effectiveness, enabling more informed treatment decisions and improved patient outcomes. The platform's clinically validated solutions are designed to be patient-centric, ensuring sustained engagement and retention for long-term data collection.
Target Audience
Cogniant targets biopharma companies, researchers, and clinicians involved in clinical trials and drug discovery for psychiatric and neurodegenerative disorders, as well as patients participating in neurological research.
Features
- Passive data collection of digital biomarkers from ubiquitous mobile devices
- Clinically validated solutions for specific neurological therapeutic areas
- AI-powered analytics for expansive phenotyping and clinical state prediction
- Scalable cohort platform for measuring the real-world effectiveness of neurological therapeutics
- Secure and anonymous data storage compliant with HIPAA, PDPA, and The Privacy Act 1988
- Patient-centric design to ensure sustained engagement and retention